Landmark Approval: U.S. FDA Nod for First-ever BTKi for CSU
The U.S. Food and Drug Administration (FDA) has approved remibrutinib (Rhapsido, Novartis) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Remibrutinib is a pill taken twice daily and does not require injections or lab monitoring. It is the first FDA-approved Bruton’s tyrosine kinase inhibitor […]